Published in Vaccine Weekly, January 24th, 2001
The vaccines are based on the company's dendritic cell cancer vaccine technology. These vaccines will potentially offer additional alternatives to cancer patients.
Cancer vaccines that have been under investigation by BioPulse previously used only patient-specific tumor antigens. This approach provides a customized and specific vaccine product for each patient. The new tumor-specific vaccines use a combination of tumor antigens designed to target a class of tumors. This strategy potentially allows for a single...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2001-01-24)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.